Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Myelodysplastic Syndromes 4Neoplasms, Plasma Cell 3Melanoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Primary Myelofibrosis 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Lymphoma, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Glioblastoma 2Burkitt Lymphoma 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Philadelphia Chromosome 1Pancreatic Neoplasms 1Osteosarcoma 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Blood Component Removal × Clear all
NCT04981119 2026-06-02

BASECAMP-1

A2 Biotherapeutics Inc.

Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡